Just catching up on the posts here. I think management has made a number of mistakes to get RVX where it is today in terms of basically having everything still really riding on BetOnMace despite apparently having a great deal of potential in a number of areas including renal, Fabry’s and the other compounds that we have heard about for two years and seen little to no forward progress.

Despite this I think, for a few reasons, we may be in the “deal zone” as SF says.

1)Poor business management aside I don’t think Don is stupid and one would think he must be motivated to get a deal done before he gets diluted along with the rest of us.

2)The looming deal may not be HL’s first choice, and not Don’s first choice either, and that the closing of this deal is probably taking so long because there is something that could possibly make this deal unnecessary.

3)The HL ROFR deal seems to have an enormous amount of wiggle (read wiggle out) room and to me it was just a way to give RVX some much needed operating funds while at the same time allowing RVX the freedom to negotiate another deal.  I think if HL came in for a total takeover they would do so with a partner.  If you look at some of their current partners wrt Heparin, especially Sanofi, Novartis and Fresenius-Kabi, there would seem to be a lot of “very good fit” potential partners for the RVX IP.  To me, if Apabetalone or any of the other RVX compounds prove successful, this would be a great way for HL to capitalize on their investment and at the same time expand their manufacturing business. ......Just a thought but I sometimes wonder how conflicted the HL RVX board member might be wrt this, “do we (HL) help RVX get a great partner or buyer now or wait until we own 42% of RVX?”

Further to all this I think Don could could still be working on whatever potential deal he was working on which caused all the delays of last years AGM. If he was hypothetically working on a complete takeover it would be very complex and time consuming due to the volume of IP involved. I believe there is likely a lot of value in the IP and personally I am hoping for a global CVR deal sooner than later. Ideally avoid dilution but at least get some upfront money into investors hands and get the IP into business hands that are capable of doing something with it in a timely manner. To me this would increase the potential of getting remedies to people in need as soon as possible and thereby increase the potential of more ROI to investors.